TECregen Secures €11M Seed Funding and Appoints New CEO to Advance Thymus Regeneration Therapeutics
核心洞察
TECregen (搜索) raised €11 million in seed funding led by Boehringer Ingelheim Venture Fund (搜索) to develop thymopoietic biologics (搜索) that rejuvenate thymic epithelial cells (搜索) and restore immune function.
The company appointed Dr. Klaas P. Zuideveld as CEO, bringing over 20 years of pharmaceutical experience to lead clinical development of their thymus regeneration platform.
TECregen (搜索)'s approach targets thymic involution (搜索), a natural aging process that leads to declining T-cell production and increased vulnerability to infections and cancer (搜索).
Swiss biotechnology company TECregen (搜索) has secured €11 million in seed funding and appointed a new chief executive officer to advance its pioneering approach to thymus regeneration, positioning the company to address a critical but underexplored mechanism underlying immune dysfunction (搜索).
The financing round was led by the Boehringer Ingelheim Venture Fund (搜索), with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds, the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. Alongside the funding announcement, TECregen (搜索) named Dr. Klaas P. Zuideveld as CEO and appointed Bo Rode Hansen as chairman of the board.
Targeting Thymic Involution and Immune Decline
TECregen (搜索) plans to use the proceeds to accelerate development of what it calls "thymopoietic biologics (搜索)," engineered molecules designed to rejuvenate thymic epithelial cells (搜索) (TECs). These cells form the structural and functional backbone of the thymus, creating the microenvironment in which immature immune cells mature into functional T cells.
The thymus plays a critical role early in life by educating T cells to recognize foreign threats while avoiding the body's own tissues, a process essential for both cancer (搜索) surveillance and the prevention of autoimmune disease (搜索). However, it is also one of the most age-sensitive organs in the body. From adolescence onward, functional thymic tissue gradually shrinks and is replaced by fat, a process known as thymic involution (搜索), leading to a steady decline in the production of new, naïve T cells.
Thymic decline is not limited to aging. Chemotherapy, radiation, stem cell transplantation, severe infections, and certain genetic disorders can damage the thymus and cause profound immune depletion. In these settings, patients may remain vulnerable to infections even when routine blood tests suggest immune recovery.
Differentiated Approach to Thymus Regeneration
TECregen (搜索)'s approach differs from other strategies in development by aiming to pharmacologically rejuvenate thymic epithelial cells (搜索) in situ, rather than supplying thymic tissue or cells. According to the company, its thymopoietics are engineered to restore thymic structure and function while minimizing off-target effects.
The company's approach centers on engineered thymopoietic ligands, a new class of growth-factor-based biologics designed to selectively regenerate thymic tissue. Growth factors have long been recognized for their regenerative potential, but their clinical use has often been limited by systemic toxicity and poor tissue specificity.
This distinction could offer advantages in scalability if translated successfully into the clinic, compared to cell-based approaches being pursued by companies like U.S.-based Thymmune Therapeutics (搜索) and Tolerance Bio (搜索), which are developing strategies using induced pluripotent stem cells to recreate or replace thymic function.
Leadership Expansion and Clinical Development Strategy
Dr. Zuideveld brings more than 20 years of experience across large pharmaceutical companies and biotech, with a strong track record spanning translational strategy, clinical development, and global regulatory execution. He has contributed to multiple IND clearances and global product approvals, and has led teams through partnering, financing and value creation milestones across several therapeutic areas.
"Klaas is a highly experienced leader with a proven ability to translate innovative science into rigorous clinical development programs," said Dr. Bo Rode Hansen, Chairman of TECregen (搜索). "As TECregen advances its novel approach to restoring thymic function, his leadership will be instrumental in shaping the company's development strategy and guiding its transition toward the clinic."
Dr. Zuideveld commented: "TECregen (搜索)'s approach to thymus regeneration addresses a central and underexplored mechanism underlying immune dysfunction (搜索). With a strong scientific foundation, an expanding pipeline, and committed investor support, the company is well positioned to advance its programs into clinical development and build a platform capable of delivering durable benefit for patients."
Investor Confidence in Emerging Field
Targeting the thymus remains technically challenging, but investors backing TECregen (搜索) see potential in restoring immune capacity at its source. "TECregen's innovative approach to thymus regeneration firmly positions the company at the forefront of targeted biologics designed to restore immune function," said Philipp Müller, investment manager at the Boehringer Ingelheim Venture Fund (搜索).
Hansen, who previously served as chief executive officer of Scandion Oncology (搜索) and was the founding president of Genevant Sciences (搜索), noted: "The team's pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune ageing and related disease."
With fresh capital and an expanded leadership team, TECregen (搜索) now faces the challenge of translating thymus biology into drug candidates that can demonstrate safety, durability, and clinical relevance. TECregen has not publicly disclosed details of its lead candidates or timelines toward clinical testing, but the company aims to strengthen immune recovery following transplantation or cytotoxic therapy, promote immune health, and enhance immune surveillance against cancer (搜索).